

EpiHeart


Cardiac Micrograft Therapy™ for treating Ischemic Scars and Heart Failure

Ischemic Scars are caused by ischemic heart diseases, including myocardial infarctions. Mortality and morbidities caused by Ischemic Scars and consequent Heart Failures are notable human and medical issues with limited treatment options globally.

Cardiac Micrograft Therapy™ is a new, currently experimental, therapy for treating Ischemic Scars. It is adjuvant and complementary to the Coronary Artery Bypass Grafting. Based on pre-clinical and clinical results (first-in-man completed), scar size can be reduce with the therapy.

EpiHeart develops, validates and commercializes the needed procedure packs and equipment needed in the therapy and drives the therapy into mainstream clinical use. This is done with partners, including clinical partners, technology partners, vendors and distribution partners.

Our approach, based on autologous, intra-operation transplantation and limited cellular manipulations, allows us to avoid regulatory challenges created by EU ATM and US HCT/P regulations and to provide unique value for the patients and for operating cardiac surgery units.



The team

At this point, the team consist of **Kai Kronström**, **Esko Kankuri** and several supporting professionals within the field of cardiac surgery and cardiology.

Kai (MSc) has been a co-founder or the founding CEO in several new medical device and high tech companies, including Injeq, Elsi Technologies, Moodmetric and Soil Scout. He holds several patents.

Esko (MD, PhD) has distinguished research career covering both cellular biology and clinical research

SPARK VALUE: We expect to meet new people trough the SPARK program that can challenge our thinking, provide relevant insights and may be help raising the funds for fair valuation.